TB Experts Rally Around New, Shortened TB Treatments
Regional meeting in Peru convened by PeerLINC, a global peer-to-peer initiative, brings together 20 countries to accelerate collaboration and scale-up
Access News
Price of Key DR-TB Medicine Drops 25% as TB Alliance’s Multi-Manufacturer Strategy Expands Access
TB Alliance’s third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving affordability and access TB Alliance
PeerLINC Recognizes One Year of Transforming Drug-Resistant TB Treatment Through Faster, More Easily Accessible Technical Assistance
The PeerLINC Knowledge Hub, an innovative peer-to-peer initiative that connects experts from countries that rapidly adopted new six-month all-oral drug-resistant
TB Alliance Works With Stop TB Canada, Viatris, and Local Physicians to Speed Pretomanid Access in Canada
Stop TB Canada has announced a streamlined process to speed up the availability of pretomanid, a key drug in the
Historically Successful Global Access Campaign for Pretomanid and BPaL-based Regimens Continues with Major Milestones in BRICS Countries
Throughout 2024, one of TB Alliance’s foremost priorities has been ensuring that pretomanid and BPaL-based regimens reach all people with
TB Alliance Applauds WHO Prequalification of Macleods Pretomanid Product
NEW YORK (November 6, 2024) — Macleods, a pharmaceutical company headquartered in India, has received prequalification from the World Health
Brazil and Philippines Accelerate Availability of Shorter Drug-Resistant Tuberculosis Treatment
MANILA (September 3, 2024) – A delegation of experts from Brazil’s National TB Program visited Manila recently to collaborate with
New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World
MANILA (25 March 2024)—TB Alliance’s new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding
High Cure Rate with Drug-Resistant TB Regimen: Results of Operational Research in Central and Southeast Asia
Indonesia, Kyrgyzstan, Philippines, Ukraine, Uzbekistan, and Vietnam presented results of LIFT-TB operational research program at the Union Conference on Lung
TB Alliance Applauds Macleods’ Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen
NEW YORK (November 13, 2023)—Indian pharmaceutical company Macleods has become the second manufacturer to launch pretomanid, a new medicine and